Mydecine Innovations Group Inc. Stock price NEO Exchange

Equities

MYCO

CA62849F2008

Biotechnology & Medical Research

End-of-day quote NEO Exchange 06:00:00 2023-10-05 pm EDT 5-day change 1st Jan Change
0.175 CAD +45.83% Intraday chart for Mydecine Innovations Group Inc. +29.63% -61.11%
Sales 2021 0.01 0.01 Sales 2022 - Capitalization 7.58M 10.25M
Net income 2021 -28M -37.89M Net income 2022 -11M -14.89M EV / Sales 2021 5,249,560,605 x
Net Debt 2021 3.01M 4.07M Net Debt 2022 153K 207K EV / Sales 2022 -
P/E ratio 2021
-1.13 x
P/E ratio 2022
-0.44 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 94.18%
More Fundamentals * Assessed data
Dynamic Chart
Mydecine Innovations Closes Partial Debt Settlement MT
Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director CI
Mydecine Innovations Group Receives Notice of Allowance from USPTO For MYCO-005 Compound MT
Mydecine Innovations Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Mydecine Innovations Group Provided Q4 2023 Business Update MT
Mydecine Innovations Group Brief: Announced Admission to Trading on AQSE Growth Market in London, UK and First Day of Dealings MT
Mydecine Innovations Group Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary CI
Mydecine Innovations Group Appoints Todd Heinzl to the Board of Directors CI
Mydecine Innovations Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Mydecine Innovations Group Inc. Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting Emp Analogues CI
Mydecine Innovations Group Inc. Auditor Raises 'Going Concern' Doubt CI
Mydecine Innovations Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Pangenomic Health Inc. completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F). CI
Mydecine Innovations Group Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
More news
Managers TitleAgeSince
Founder - 13-09-26
Founder - 13-09-26
Chief Executive Officer - 18-06-21
Members of the board TitleAgeSince
Chief Executive Officer - 18-06-21
Founder - 13-09-26
Founder - 13-09-26
More insiders
Mydecine Innovations Group Inc. is a Canada-based biopharmaceutical company. The Company’s principal activities are research, drug development and clinical trials of psilocybin products. The Company offers healthcare professionals a variety serotonin-modulating medications by developing drug families derived from Psilocybin and MDMA. The Company is developing several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. It is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.
More about the company
  1. Stock
  2. Equities
  3. Stock Mydecine Innovations Group Inc.
  4. Stock Mydecine Innovations Group Inc. - NEO Exchange